Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Perinatal outcome following third trimester exposure to paroxetine.

Costei AM, Kozer E, Ho T, Ito S, Koren G.

Arch Pediatr Adolesc Med. 2002 Nov;156(11):1129-32.

PMID:
12413342
2.

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W.

J Clin Psychiatry. 2004 Feb;65(2):230-7.

PMID:
15003078
3.

Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?

Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S.

J Psychopharmacol. 2005 Sep;19(5):554-7.

PMID:
16166193
4.

Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study.

Galbally M, Lewis AJ, Lum J, Buist A.

Aust N Z J Psychiatry. 2009 Sep;43(9):846-54. doi: 10.1080/00048670903107583.

PMID:
19670058
5.

Neonate characteristics after maternal use of antidepressants in late pregnancy.

Källén B.

Arch Pediatr Adolesc Med. 2004 Apr;158(4):312-6.

PMID:
15066868
6.

Perinatal outcome following third-trimester exposure to paroxetine: an alternative interpretation.

Pryse-Phillips W, Yuen DE, Pham B.

Arch Pediatr Adolesc Med. 2003 Jun;157(6):601. No abstract available.

PMID:
12796244
7.

Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.

Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G.

Arch Pediatr Adolesc Med. 2006 Feb;160(2):173-6.

PMID:
16461873
8.

[Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review].

Agut-Quijano T, Martínez-Nadal S, Elizari-Saco MJ, Sala-Castellví P, Vila-Cerén C, Raspall-Torrent F.

Rev Neurol. 2006 Jun 1-15;42(11):660-2. Spanish.

9.

Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study.

Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M.

BJOG. 2008 Jan;115(2):283-9. Epub 2007 Sep 27.

10.

First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.

Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D.

Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27.

PMID:
17187388
11.

Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels.

Knoppert DC, Nimkar R, Principi T, Yuen D.

Ther Drug Monit. 2006 Feb;28(1):5-7.

PMID:
16418684
12.

[Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine].

Salvia-Roigés MD, Garcia L, Goncé-Mellgren A, Esqué-Ruiz MT, Figueras-Aloy J, Carbonell-Estrany X.

Rev Neurol. 2003 Apr 16-30;36(8):724-6. Spanish.

13.

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Arch Gen Psychiatry. 2006 Aug;63(8):898-906.

PMID:
16894066
14.

Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Malm H, Klaukka T, Neuvonen PJ.

Obstet Gynecol. 2005 Dec;106(6):1289-96.

PMID:
16319254
15.

Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.

Nordeng H, Lindemann R, Perminov KV, Reikvam A.

Acta Paediatr. 2001 Mar;90(3):288-91.

PMID:
11332169
16.

Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome.

Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G.

Am J Obstet Gynecol. 2005 Dec;193(6):2004-9.

PMID:
16325604
17.

First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.

Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT.

Birth Defects Res A Clin Mol Teratol. 2010 Feb;88(2):94-100. doi: 10.1002/bdra.20641.

PMID:
19937603
18.

[Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy].

Cissoko H, Swortfiguer D, Giraudeau B, Jonville-Béra AP, Autret-Leca E.

Arch Pediatr. 2005 Jul;12(7):1081-4. French.

PMID:
15964522
19.

Prolonged neonatal complications after in utero exposure to fluoxetine.

Alehan F, Saygi S, Tarcan A, Gürakan B.

J Matern Fetal Neonatal Med. 2008 Dec;21(12):921-3. doi: 10.1080/14767050802266899.

PMID:
18985556
20.

Neonatal paroxetine withdrawal syndrome.

Stiskal JA, Kulin N, Koren G, Ho T, Ito S.

Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F134-5.

Supplemental Content

Support Center